Toyota|$17.81 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.68 (¥4,237)-1.40%▼ (in JPY terms)
SoftBank|$24.39 (¥3,872)+13.88%▲ (in JPY terms)
MUFG|$21.63 (¥3,435)+2.05%▲ (in JPY terms)
Keyence|$473.61 (¥75,200)+5.06%▲ (in JPY terms)
Nintendo|$53.23 (¥8,452)-1.79%▼ (in JPY terms)
NTT|$1.04 (¥165)-0.42%▼ (in JPY terms)
Takeda|$41.52 (¥6,593)-1.20%▼ (in JPY terms)
Tokyo Electron|$56.72 (¥9,006)+6.05%▲ (in JPY terms)
Recruit|$113.11 (¥17,960)+1.67%▲ (in JPY terms)
ITOCHU|$14.84 (¥2,356)+0.26%▲ (in JPY terms)
Honda|$11.67 (¥1,853)-1.62%▼ (in JPY terms)
Shin-Etsu|$35.63 (¥5,658)+3.99%▲ (in JPY terms)
Tokio Marine|$3.68 (¥584)+0.03%▲ (in JPY terms)
Fast Retailing|$513.72 (¥81,570)+0.94%▲ (in JPY terms)
Toyota|$17.81 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.68 (¥4,237)-1.40%▼ (in JPY terms)
SoftBank|$24.39 (¥3,872)+13.88%▲ (in JPY terms)
MUFG|$21.63 (¥3,435)+2.05%▲ (in JPY terms)
Keyence|$473.61 (¥75,200)+5.06%▲ (in JPY terms)
Nintendo|$53.23 (¥8,452)-1.79%▼ (in JPY terms)
NTT|$1.04 (¥165)-0.42%▼ (in JPY terms)
Takeda|$41.52 (¥6,593)-1.20%▼ (in JPY terms)
Tokyo Electron|$56.72 (¥9,006)+6.05%▲ (in JPY terms)
Recruit|$113.11 (¥17,960)+1.67%▲ (in JPY terms)
ITOCHU|$14.84 (¥2,356)+0.26%▲ (in JPY terms)
Honda|$11.67 (¥1,853)-1.62%▼ (in JPY terms)
Shin-Etsu|$35.63 (¥5,658)+3.99%▲ (in JPY terms)
Tokio Marine|$3.68 (¥584)+0.03%▲ (in JPY terms)
Fast Retailing|$513.72 (¥81,570)+0.94%▲ (in JPY terms)

2026-03-02 Yamaha Motor Co.,Ltd. “March 2, 2026 [Corporate] A small water purification device will be installed in Iwata City, Shizuoka Prefecture, and a demonstration experiment will begin in April. Collaboration with the city will be carried out to verify its use in the event of a disaster.”

2026-03-02 Yamaha Motor Co.,Ltd. “March 2, 2026 [Corporate] A small water purification device will be in … 続きを読む

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in cisplatin-eligible muscle-invasive bladder cancer were presented at the 2026 American Society of Clinical Oncology (ASCO GU) Annual Meeting.”

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate … 続きを読む